RHHBY•benzinga•
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
Summary
Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga